Phase II trial of Neu2000 in Korean patients with ischemic stroke

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 24 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 May 2016 According to a GNT Pharma media release, this trial is expected to initiate in the second quarter of 2016 and to complete in 2017.
16 May 2016 According to a GNT Pharma media release, the Korea Ministry of Food and Drug Safety has approved the company's Investigational New Drug (IND) application to initiate a Phase II clinical study of Neu2000 in ischemic stroke patients receiving endovascular therapy.
16 May 2016 According to a GNT Pharma media release, status changed from planning to not yet recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com